menu

Patient Case: Timing and Selection of NRG1-fusion Targeted Eligible Patients

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Targeting NRG1 Fusion Positive Tumors: An Actionable Oncogenic Driver to Outcomes

Patient Case: Timing and Selection of NRG1-fusion Targeted Eligible Patients

Minute CME/CE™
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    The purpose of this program is to create awareness about the emergence of NRG1 fusions as a clinically actionable target, leading to new opportunities to increase patient referral due to a greater understanding of this ERBB[/HER]-targeted agents in NRG1 fusion-positive cancers. Researchers still do not fully understand many aspects of this targeting, raising the importance of foundational education to apprise clinicians of the latest mechanistic and preclinical data, so they become more comfortable to ask and detect and then refer.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including Physicians, Community Oncologists, Pathologists, Nurses and Pharmacists, as well as other clinicians that are involved in the management of patients with NRG1 fusion tumors.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Recognize NRG1 fusions as a clinically actionable target and differentiate available testing platforms for identifying NRG1 fusions and interpreting test results 
    2. Refer patients with NRG1 fusions to appropriate centers conducting clinical trials 
    3. Explain the rationale for ErbB-targeted agents in NRG1 fusion-positive cancers 
    4. Describe the process for referral and enrollment in ongoing registrational clinical trial targeting NRG1 fusions
  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • Faculty Disclosure of Commercial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    The following faculty has reported relationships with ineligible companies:

    Stephen Liu, MD, faculty for this educational event, received a research grant from Alkermes, Bayer, Blueprint, Bristol-Myers Squibb, Elevation Oncology, Genentech, Gilead, Lilly, Merck, Merus, Nuvalent, Pfizer, Rain Therapeutics, RAPT, and Turning Point Therapeutics; and receives consulting fees from Amgen, AstraZeneca, Bayer, Beigene, Blueprint, Boehringer-Ingelheim, Bristol-Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Lilly, MSD, Novartis, Regeneron, Sanofi, Takeda, and Turning Point Therapeutics.

    Efrat Dotan, MD, faculty for this educational event, received a research grant from Lilly, Incyte, Relay, AstraZeneca, Medimmune, Zymeworks, NGM biopharmaceuticals and Ipsen; and receives consulting fees from Incyte, Taiho, G1 therapeutics, Pfizer; Helsinn, QED and Basilea.

  • Planners and Managers Disclosure List

    The following reviewers/planners have reported no relationships with ineligible companies:

    Megan Reimann, PharmD, BCOP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by an independent educational grant from Elevation Oncology. 

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 8/17/2022 through 8/17/2023, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Presenters

Facebook Comments

Customize your experience based on your profession
Profession
Registration is a short process and your information will be kept safe.
Schedule7 Dec 2022